Translational Entrepreneur

Lead Research Organisation: University of Edinburgh
Department Name: Royal (Dick) School of Veterinary Scienc

Abstract

The University of Edinburgh and the MRC are piloting a new approach to take Edinburgh s world-leading medical science and translate this into direct benefits for patients and the local and wider community. Both commercial and non-commercial benefits are to be supported.

Technical Summary

The University of Edinburgh s College of Medicine and Veterinary Medicine, exploiting a longstanding focus on interdisciplinary research, wishes funding in part support of a pilot project to test the concept of a Translational Entrepreneur to galvanise a step-change in translation of our world-leading biomedical science (14th in World, 5th in Europe, THES, Nov 2005) into improvements in human (and animal) health.
 
Description Business in the Parliament Conference-Scotland
Geographic Reach National 
Policy Influence Type Participation in advisory committee
 
Description Economy Committee Scottish Parliment
Geographic Reach National 
Policy Influence Type Gave evidence to a government review
 
Description Holyrood Expert panel in life science business to Scottish Executive
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in advisory committee
 
Description LiSAB ( life science advisory board )
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in advisory committee
Impact LiSAB is a joint industry, enterprise and government strategy team that plays a crucial role in ensuring Scotland has the best possible environment for fledgling technologies and established players alike. It fosters support and discussion between key players in the life sciences sector and those responsible for government policy-making at the very highest level. LiSAB has a very active remit; to develop and drive overall life sciences strategy in Scotland; developing an environment where ingenuity and innovation can create jobs and wealth for Scotland, as well as genuine benefits for the global community.
 
Description Meeting with Governor Bank England
Geographic Reach National 
Policy Influence Type Participation in a national consultation
Impact Key discussion around bank finance. Clear changes in Government approach to SME lending.
 
Description Aquila Biomedical (Regional Selective Assistance)
Amount £230,000 (GBP)
Organisation Government of Scotland 
Sector Public
Country United Kingdom
Start 09/2016 
End 03/2018
 
Description BioQuarter ESCF fund NeurocentRx Pharma proposition support
Amount £22,848 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 09/2012 
End 05/2013
 
Description BioSKAPE (Fibromed)
Amount £67,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 07/2012 
End 03/2013
 
Description Confidence in Concept
Amount £700,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 12/2012 
End 06/2014
 
Description Edinburgh BioQuarter Aquila Biomedical market
Amount £10,000 (GBP)
Funding ID GQ2514 
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 08/2012 
End 08/2013
 
Description Edinburgh BioQuarter Fibromed validation
Amount £19,370 (GBP)
Funding ID GQ2630 
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 03/2012 
End 09/2013
 
Description Edinburgh BioQuarter Funding/Edinburgh bioQuarter
Amount £6,000,000 (GBP)
Organisation University of Edinburgh 
Sector Academic/University
Country United Kingdom
Start 04/2010 
End 04/2015
 
Description Executive Director Designate ERDF Aquila Biomedical
Amount £36,000 (GBP)
Organisation European Commission 
Department European Regional Development Fund (ERDF)
Sector Public
Country European Union (EU)
Start 11/2011 
End 08/2012
 
Description Executive Director Designate Fibromed CBO
Amount £36,000 (GBP)
Organisation European Commission 
Department European Regional Development Fund (ERDF)
Sector Public
Country European Union (EU)
Start 07/2012 
End 03/2013
 
Description Executive Director Designate Fibromed CEO
Amount £36,000 (GBP)
Organisation European Commission 
Department European Regional Development Fund (ERDF)
Sector Public
Country European Union (EU)
Start 07/2012 
End 03/2013
 
Description Executive Director Designate NeurocentRx Pharma MD
Amount £36,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 11/2012 
End 07/2013
 
Description Galapagos Edinburgh Cancer Discovery Unit
Amount £600,000 (GBP)
Organisation Galapagos Genomics 
Sector Private
Country Belgium
Start 09/2012 
End 09/2014
 
Description Generation Scottland Resource Access Fibromed Ltd
Amount £30,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 01/2012 
End 12/2012
 
Description Graduate Internship Aquila BioMedical
Amount £7,500 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 02/2013 
End 02/2014
 
Description Graduate Internship Aquila Biomedical
Amount £7,500 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 03/2011 
End 03/2012
 
Description Graduate Internship Aquila Biomedical
Amount £7,500 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 11/2012 
End 04/2013
 
Description High Growth Unit (Fibromed Products)
Amount £50,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 03/2016 
End 12/2017
 
Description Initiating knowledge transfer (IKT) Edinburgh research & innovation/Edinburgh Research & Innovation
Amount £7,000 (GBP)
Organisation University of Edinburgh 
Sector Academic/University
Country United Kingdom
Start 12/2010 
End 03/2011
 
Description Innovation Grant (FibromedProducts)
Amount £5,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 06/2016 
End 12/2019
 
Description Innovation Grant Pain Models Aquila
Amount £16,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 01/2012 
End 01/2013
 
Description Interim Management Support Fibromed
Amount £8,250 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 07/2012 
End 10/2012
 
Description International Manager for Hire Aquila Biomedical
Amount £25,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 08/2012 
End 08/2013
 
Description Investment (Neurocentrx Pharma)
Amount £300,000 (GBP)
Organisation Neurocentrx Pharma 
Sector Private
Country United Kingdom
Start 04/2017 
End 01/2020
 
Description Investment in NeurocentRx Ltd
Amount £300,000 (GBP)
Organisation Equity Gap 
Sector Private
Country United Kingdom
Start 02/2016 
End 03/2019
 
Description Investor Ready Grant Aquila Biomedical
Amount £10,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 12/2012 
End 12/2013
 
Description LSBAS support of diagnostic venture
Amount £15,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 01/2008 
End 09/2008
 
Description LSBAS support of in vivo venture
Amount £15,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 01/2008 
End 11/2008
 
Description MRC Developmental Pathway Funding Scheme (DPFS)
Amount £2,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2009 
End 03/2011
 
Description Marketing Grant Aquila Biomedical
Amount £7,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 02/2012 
End 02/2013
 
Description NC3R MRC DPFS (Functional Optical Imaging in mice and man)
Amount £100,000 (GBP)
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Private
Country United Kingdom
Start  
 
Description Neuropathic pain trial agent production
Amount £30,000 (GBP)
Organisation NHS Lothian 
Sector Public
Country United Kingdom
Start 12/2012 
End 06/2013
 
Description Proof of Concept (TRPM8)
Amount £400,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 02/2007 
End 10/2009
 
Description Proof of Concept support of psychiatry patents
Amount £5,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 06/2008 
End 12/2008
 
Description SMART Aquila BioMedial
Amount £100,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 12/2013 
End 12/2014
 
Description SMART Aquila Biomedical
Amount £70,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 02/2011 
End 03/2012
 
Description Scottish Universities Life Sciences Alliance (SULSA)
Amount £50,000 (GBP)
Organisation Scottish Universities Life Sciences Alliance 
Sector Academic/University
Country United Kingdom
Start 01/2009 
End 03/2010
 
Description Tool Box for MHRA submission
Amount £50,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 05/2008 
End 12/2008
 
Description undergraduate placement programme (Aquila BioMedical)
Amount £14,000 (GBP)
Organisation Scottish Universities Life Sciences Alliance 
Sector Academic/University
Country United Kingdom
Start 08/2016 
End 07/2022
 
Description Aquila BioMedical -Histoplex LLP 
Organisation Aquila Histoplex
Country United Kingdom 
Sector Private 
PI Contribution The mechanism of action company Aquila Biomedical provides an established CRO laboratory and an expanding set of clients
Collaborator Contribution LLP with an University team providing advanced histology testing including the first UK accredited RNAscope service.
Impact support of Aquila services in autoimmune disease, immuno-oncology through testing of histology samples from model systems and the clinic, and income generation. This LLP has been successful for Aquila and Histoplex team that the LLP will be dissolved early 2017 and will formally become a division of the profitable global company.
Start Year 2017
 
Description Aquila Biomedical acquired by Concept Life Sciences 
Organisation Concept Life Sciences
PI Contribution Aquila Biomedical was acquired by Concept Life Sciences in October 2017. Since February 2018 Concept Life Sciences has been part of Spectris plc, a FTSE250 company. Aquila Biomedical employs 30 members of staff and generated £3.8m revenue in 2018. It is anticipated that a £5m+ turnover and an increase in staff numbers to around 50 will be achieved by 2020.
Collaborator Contribution The acquisition will progress the company in turnover, number of staff, resources etc.
Impact One of the first CROs to be built from an immunology base and one of the first to offer immune-oncology services. Outcome from the acquisition should result in higher £ turnover and increase in staff numbers. No other CRO offered such a broad range of assays in the immuno-oncology service or had an assay which could measure reversal of T cell exhaustion.
Start Year 2017
 
Description Edinburgh Partners Devices and Diagnostics 
Organisation Heriot-Watt University
Department School of Engineering & Physical Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution University of Edinburgh led a collaboration with Heriot-Watt that includes Confidence in Concept funding covering Devices Diagnostics and Diagnostics Apps for hand help devices. Edinburgh brings the medical and unmet need and computing aspects through School of Informatics.
Collaborator Contribution Heriot Watt brings proven engineering and fabrication skills/ capabilities applied to medical devices
Impact The outputs are listed under MC_PC_12014 We have expanded the collaboration beyond the funded projects in MC_PC_12014 into a project on birthing mirror and a histology water bath. We have combined with Heriot Watt to bring together a further CiC application in October 2014
Start Year 2012
 
Description Fibromed with Institute of Cancer Research 
Organisation Institute of Cancer Research UK
Country United Kingdom 
Sector Academic/University 
PI Contribution Scientists are providing stem cell hepatocytes
Collaborator Contribution The pharmacology group are characterising the performance of these cells against the gold standard primary human hepatocytes
Impact Data on optimisation of the product
Start Year 2013
 
Description NHS Lothian 
Organisation NHS Lothian
Country United Kingdom 
Sector Public 
PI Contribution We are building on the model developed by the Translational Entrepreneur appointment with the College of Medicine & Vet Medicine, working in collaboration to enhance technology transfer from University of Edinburgh and NHS Lothian
Collaborator Contribution Funding of an Enterprise Associate position to work with the Translational Entrepreneur and team towards extending our area of operation to build understanding, help culture change and deliver commercial outputs for NHS Lothian
Impact With NHS Lothian, the Entrepreneur set up a parallel system to the one he ran in the University. This is now formally part of the Edinburgh BioQuarter. NHS Lothian have paid for a post, a Business dev exec, to follow mentoring through the EiR and bus. dev manager and adopt the process of working with PIs to address unmet needs by developing imaginative yet milestone driven projects & programmes, building teams, taking advantage of industry contacts and delivering products and services that meet these unmet needs. The associate continues to build translational projects with one not for profit company formed ipSOX www.ipsox.co.uk by 2 nurses and a consultant from the metabolic unit to provide bespoke covers for insulin pumps. ipSOX has been formed from NHS Lothian and Napier University and collaborates extensively with a UK company on design and manufacture of covers that already are achieving exports and significant orders through users and manufactures. We are using this company to train an intern, who is delivering new media communication as part of diabetes month with "memorable diabetes momments" to expand marketing reach. This is an example of harnessing enthusiastic professionals into a non conventional translational delivery approach that has alrady donated to diabetes research and is building new products for pump users and will shortly be applying profits to fund insulin pump research applications. The brand is being transferred to a company producing insulin pen covers http://pentrim.com/ who will continue the supply to customers, donating profits to JDRF and developing the sports range. The Business Development Executive continues to build multiple translational projects for the NHS and has accessed valuable sources of funds to provide catalytic investment into projects.
Start Year 2009
 
Description ipSOX Funky Fone Sox 
Organisation Funky Fone Sox Company
Country United Kingdom 
Sector Private 
PI Contribution The ipSOX team designed the products to be manufactured
Collaborator Contribution Funky Fone Sox organised the manufacturing of the ipSOX insulin pump covers at no added cost
Impact Donations made to Diabetes UK
Start Year 2011
 
Title MBP Tracker Mouse 
Description MBP-Tracker technology allows us to specifically follow those T cells that drive pathology, quantify them in different organs (including the CNS) and to measure the activation of a range of key disease-associated functions within these T cells 
IP Reference  
Protection Protection not required
Year Protection Granted
Licensed Yes
Impact Aquila BioMedical is using the technology in industrial collaborations on multiple sclerosis drug discovery projects
 
Title Aquila Biomedical venture 
Description Aquila biomedical was incorporated as a company late 2011. Aquila is a preclinical services venture specilaising in turning high-end biological assays (assays based on advanced molecular understanding of disease processes) into screening tools for drug candidate selection. We started in MS with novel MOA models for demyelination and remyelination. The company has expanded more broadly in autoimmunity added pain including cancer pain. Plan to move to other areas - cancer and inflammation and human cell models. This venture has broad support in the University. Now established, it is providing a mechanism for efficient use of many academic assets that are currently underutilised for commercial purposes. The business team has been built and investment obtained and now the company is fully operation and in addition to offering services is building new MOA models. 
Type Support Tool - For Fundamental Research
Current Stage Of Development Small-scale adoption
Year Development Stage Completed 2010
Development Status Actively seeking support
Impact Company formed, 2x SMART award recieved and 3 employees actively validating models in auto immune MS and pain. aquila-bm.com Now building MS in a dish model with license of specialist mouse line from DKFZ 
URL http://www.aquila-bm.com
 
Title Clinical Imaging Services venture 
Description Under development through our extension to NHS with appointed BDE now 3 year in post. Concept to capitalise on collective imaging capabilities in various areas ( neuroscience, heart, lung) into a clinical services company. Currently academics do a level of service work that is beneficial though eats time and is not capitalised on fully by the University/NHS. Using the translator's connections to build business team and generate a company. This is an outcome that the clinicians have asked for help in developing. A company vehicle will improve revenue directly back to the core facility that already does a level of contract work with industry but loses its income to a broad University pot. With a business/sales team we expect to increase hugely demand and exposure and hire dedicated staff. The University will benefit from this exposure but also directly financially through consultancy arrangements and as a shareholder. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2010
Development Status Closed
Impact was developed as consultancy 
 
Title Clinical Lab services 
Description This opportunity is being developed under our new line of activity with the NHS and our BDE appointed, now 1 year as an FTE. Development of NHS resources from a testing (receivership) based model to an organisation capable of capitalising on its inherent assets (strategic & proactive, business orientated) - particularly it's combination of speed and expertise to develop new assays for disease (worldwide flu variants good example), and its expertise in pathology. Two approaches are being developed. One is an extension of core services. Second is a vehicle through which the NHS can build strategic alliances through Translator connections to companies (eg: Sequenom and HistoRx) and expertise (eg: Prof Chris Price) 
Type Management of Diseases and Conditions
Current Stage Of Development Initial development
Year Development Stage Completed 2010
Development Status Closed
Impact impact to be realised. Process too early at present. Hope to be first EU site for novel genetic tests for selection of patients for wet MD. Further tests under discussion with major US molecular analysis innovator. 
 
Title Cognition product 1 - AD test 
Description this is a laptop based test for AD based on dual task responses and their interpretation. The algorithms have been refined based on over 30 years research (Bob Logie, de laSalla) . We have aligned with Toshiba to help us in the future access worldwide markets. At present we are seeking funds to further validate and refine the test in ongoing large clinical trials. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2010
Development Status Actively seeking support
Impact This will be commercialised for sale in the US and EU, have revenues generated for the University and funders ( along with normal T&Cs). 
 
Title Fibromed Products 
Description A company based on a combination of stem cell science ( hepatocytes generated through iPS) and a novel polymer support (for differentiation & growth) to be used as a screening tool for pharma in selecting against hERG channel activators, metabolic breakdown products, or patients likely to adversely react in trials. Once hepatocyte established, Fibromed may develop complementary areas (eg: cardiomyocyte screening). 
Type Support Tool - For Medical Intervention
Current Stage Of Development Initial development
Year Development Stage Completed 2012
Development Status Actively seeking support
Impact Company has been formed (fibromed.co.uk) with 3 leading accademics and HM. Biobank of phenotyped and genotyped cells for iPS development is under construction working with hospitals and Generation Scotland biobank. Hepatocytes are being validate by industry collaborations. Two Executives are retained under HGU funding 
URL http://www.fibromed.co.uk
 
Title Insulin pump holder 
Description This opportunity has been developed under our activity with the NHS and our BDE appointed, now 2 year in as mentioned in 'collaborations' section. We are developing a soft, flexible cover for diabetes monitors to suit patients needs. We are doing this with a company called ' Funky phone Sox'. We have established a NFP to deal with proceeds that will be donated back to the Metabolic Unit in Edinburgh 
Type Support Tool - For Medical Intervention
Current Stage Of Development Small-scale adoption
Year Development Stage Completed 2010
Development Status Under active development/distribution
Impact A good example of how an unmet need that patients and staff have identified is being translated to a product through with NHS savings through innovation can be realised, with determination on development and imagination on proposing a NFP. This is also an example of an opportunity that despite being valuable and with a significant element of 'culture change' attached to the outcome, might otherwise not be developed as it does not fit with typical TTO metrics (eg: disclosure, patent, licensable). Translator connections include materials experts to adapt current form and media and governance support. 
URL http://www.ipsox.co.uk
 
Title Speckled Computing - solutions for e-health 
Description This opportunity is being developed under our new line of activity with the NHS and our BDE appointed, now 3 year in post. Speckled computing has telehealth applications in movement based monitoring in the home and in ITUs or wards. This is a multi healthcare application based technology involving major multidisciplinary teams. Our BDE with translator guidance runs teams that cross medicine, infomatics and support services (edinburgh clinical trials and statistics) as well as company collaborators. There are at least 4 applications. Two (COPD and post operative care) are teams actively seeking funds ( HICF - through to round 2) and pertners. Phillips and Tunstall are connections made through the MRC translator. The Tunstall collaboration is part of a 1.5m HICF application presently through to round 2 assessment. 
Type Management of Diseases and Conditions
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2010
Development Status Actively seeking support
Impact notable company collaborations and multiple funding applications. Too early for health impact. 
 
Title chronic pain treatment 
Description Agonist for TRPM8 as topical treatment for chronic pain funded by SE POC. New funding warded for 6 month chemistry programme from Edinburgh bioQuarter - bridge funding for continuation and talent retention. Now complete 2010. New funding for full team July 2010 from MRC pilot portfolio award. In progress through to end in 2011 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2009
Development Status Under active development/distribution
Impact in advanced discussion with Pharma 
 
Title chronic pain treatment 2 
Description we are developing a reformulation of an existing drug used as currently as an adjuvant treatment for chronic neuropathic pain experienced by cancer patients. A phase III is currently running with an oral capsule formulation. Currently in paractive this drug is taken intramuscularly or in liquid oral form. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2010
Development Status Under active development/distribution
Clinical Trial? Yes
Impact We seek to develop this first as a special and later in other more refined oral liquid capsules rather than the loose filled powder capsule currently in trial. This could bring revenue to the University and a spin out company and encourage other clinicians to think about IP that is contained within their studies. This type of IP is not typically developed by institutes, as it would be pre-selected against due to the development work required and it's non patentable nature. 
URL https://clinicaltrials.gov/show/NCT01316744
 
Title chronic pain treatment 3 
Description An open label study with a well known and available compound has been completed. The study looked at a variety of cancer drug induced pain patients and their response. The compound is now seeking funds for an efficacy study. It will in parallel be developed as a specials product and later be incorporated into new topical formulations (gel, patch, spray) 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2010
Development Status Under active development/distribution
Impact This could bring revenue to the University and a spin out company and encourage other clinicians to think about IP that is contained within their studies. 
 
Company Name Aquila Biomedical Ltd 
Description Aquila Biomedical is a research service company with strong links to the University. http://www.aquila-bm.com 
Year Established 2011 
Impact Company formed, 2 SMART awards received and 20 employees actively validating models in auto immune MS and pain with pharmaceutical contracts in place. Global client base US, EU and Japan Pharma and Biotech. Company now delivering immuno-oncology models for drug discovery. Formed an LLP Aquila Histoplex to provide advanced histology. SO304736. Due to success this LLP is now being incorporated as a division of Aquila http://histoplex.co.uk/ Aquila is now trading profitably and is scheduled to be at 30 employees in early 2018.
Website http://www.aquila-bm.com/index.html
 
Company Name Fibromed Products Ltd 
Description Company has been formed (fibromed.co.uk) with 3 leading accademics and HM. Biobank of phenotyped and genotyped cells for iPS development is under construction working with hospitals and Generation Scotland biobank. Hepatocytes are being validate by industry collaborations. http://www.fibromed.co.uk. The company was wound up in 2015 due to failure to close investment round. 
Year Established 2013 
Impact Agreements with Generation Scotland, Roslin Cells and University will underpin the growth of the company. Fibromed Product was formed from Fibromed Ltd launched in 2011. The companies hepatocyte system was described by Oliver Flint of BMS as the best available for testing hepatotoxic liabilities of drug molecules.
Website http://www.fibromed.co.uk/
 
Company Name ipSOX ltd 
Description www.ipsox.co.uk ipSOX covers for insulin pumps come in a selection of colours and designs that stretch to fit your insulin pump. All ipSOX profits are reinvested to support diabetes care. 
Year Established 2011 
Impact Provided over 20000 covers and is currently designing products for use in sporting activities.
Website http://www.ipsox.co.uk
 
Company Name NeurocentRx Pharma 
Description www.neurocentrx.com The company is focussed on building a platform of products for treatment of chronic neuropathic pain and will be launched its first product as specials in 2015. The product is being supplied based on hospital request across the UK. The topical product uses menthol a natural agonist of TRPM8 that has been demonstrated in a 50 patient trial to be effective in cancer treatment induced neuropathic pain. NeurocentRx has licensed a University patent for the use of menthol in this indication that is now granted in Europe. NeurocentRx Pharma has also licensed the data from a large clinical trial on oral ketamine as will examine the data for potential support of a regulatory study when the study reports. 
Year Established 2013 
Impact The company has raised over £500,000 seed investment and grants.
Website http://www.neurocentrx.com/
 
Description BIO International US meeting - BIO Partnering 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Business Partnering Forum for Pharma / Biotech and CROs. Seeking opportunities for company propositions.

Potential future clients for BioQuarter development. Potential future company partners .
Year(s) Of Engagement Activity 2008,2009,2010
 
Description BIO business - Geneva 2008 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Platform shared with Roche on innovative company spin-out plans for a CNS company.

none yet
Year(s) Of Engagement Activity 2008
 
Description BioDundee conference 2010 -chair of panel on Building Alliances 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact chair of panel that focused on partnerships and collaborations within the life science sector. event focused on science-business community including life science entrepreneurs

engagement of VC interest for bioQUarter, alliance forged with inward investment company for new venture, partnerships for translational programmes in NHS and the University
Year(s) Of Engagement Activity 2010
 
Description Biotrinity Investor conference Fibromed 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact One of UK largest investor conferences, presenting to more than 100 investors.

Engagement with investors and Pharma executives
Year(s) Of Engagement Activity 2012
 
Description Commercialisation Seminar 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact The entrepreneur in residence and effect on spin-out activity. Proof of Concept Programme Symposium on creating high value spin-outs: Glasgow

Connections made to senior business and academic colleagues
Year(s) Of Engagement Activity 2008
 
Description Commercialisation seminar 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Presented in seminar on commercialisation Division of Pathway Medicine University of Edinburgh

Interest in translational activity. Measured by two subsequent DPFS Portfolio applications
Year(s) Of Engagement Activity 2007
 
Description Conference For Generation Scotland 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Health professionals
Results and Impact Academic and Pharma executive exploring how to use biobanks

continued engagement on use of Generation Scotland for generation of specific iPS lines for toxicity testing
Year(s) Of Engagement Activity 2012
 
Description Conference Panel 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Mixed audience of Pharma and Biotech executives -who engaged in the discussion on the changes in the drug development industry and how to best access expertise from accademia

Follow up with several companies
Year(s) Of Engagement Activity 2011
 
Description Globalscot Meeting Hong Kong 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? Yes
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Presentation on Scottish Life Science at globalscot meeting Hong Kong. December 2008

meeting with influential international business people and investors, initiated concept of incubator fund
Year(s) Of Engagement Activity 2008
 
Description Globalscot Meeting New York 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Workshop on Scottish Life Science at globalscot meeting New York. December 2007.

Recognition of opportunity and issues by this influential group
Year(s) Of Engagement Activity 2007
 
Description Investor Meeting Fibromed 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Approximately 50 investors were present for the event. Engagement with 2 investors was initiated.

Fibromed was invited to present at BioTrinity 2012
Year(s) Of Engagement Activity 2011
 
Description Judge on Venture Competition 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Finals of Dundee Students Venture competition. Presentations questions and award

Trias Gkikopoulos has been named the winner of the University of Dundee's Venture 2013 competition for his business idea of designing and building an unmanned aircraft for civil, commercial and scientific use. National press.
Year(s) Of Engagement Activity 2013
URL http://www.dundee.ac.uk/pressreleases/2013/march13/ventureprize.htm
 
Description Judge on Venture Competition 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact Finals of Dundee Students Venture competition to award £10,000 in prize money

continue to engage with the Design aid+ team on accessories for junior doctors
Year(s) Of Engagement Activity 2012
 
Description Medical Training on Pharmaceutical Product Development 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Health professionals
Results and Impact Invited speaker to put the drug industry in context

Engagement from a Glasgow Doctor on commercial options
Year(s) Of Engagement Activity 2012
 
Description UNICO 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Entrepreneurs in residence: strangers in our midst? UNICO CONFERENCE Nottingham - 5-7 December 2007

Continued support from Scottish Enterprise
Year(s) Of Engagement Activity 2007